LONDON, July 1, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Earnings Review released its analysts' notes regarding James Fisher & Sons plc (LON: FSJ), Severn Trent Plc (LON: SVT), Synergy Healthcare plc (LON: SYR), Dairy Crest Group plc (LON: DCG) and Bodycote PLC (LON: BOY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://earnings-review.com/4305-100free.
James Fisher & Sons plc Analyst Notes
On June 23, 2014, James Fisher & Sons plc (James Fisher) announced the acquisition of the entire share capital of Testconsult Limited (Testconsult) and its subsidiaries for a total cash consideration of £8.0 million. James Fisher informed that Testconsult provides monitoring, instrumentation and testing services and also designs and produces specialist testing equipment used in over 70 countries, worldwide. The acquisition of Testconsult will expand and complement the existing range of services offered by James Fisher's Strainstall Monitoring business. Nick Henry, CEO, James Fisher, said, "We are delighted to welcome Testconsult into the James Fisher group and we look forward to benefitting from the enlarged opportunity which the combination of Strainstall Monitoring and Testconsult will present, expanding our activities in testing and monitoring with complementary skills, products and services. We intend to build on our combined strengths, particularly in international markets." The full analyst notes on James Fisher are available to download free of charge at:
Severn Trent Plc Analyst Notes
On May 29, 2014, Severn Trent Plc (Severn Trent) released its FY 2014 financial results (period ended March 31, 2014). The Company reported FY 2014 turnover of £1.9 billion, up 1.4% YoY. FY 2014 profit attributable to owners of the Company came in at £433.8 million or 181.3 pence per diluted share, compared to a profit of £216.0 million or 90.5 pence per diluted share in FY 2013. As on March 31, 2014, the Company's cash and cash equivalents were £123.2 million, as compared to £403.6 million as on March 31, 2013. Severn Trent's board has proposed a final dividend of 48.24 pence, which if approved at the Annual General Meeting on July 16, 2014, will be paid on July 25, 2014 to shareholders on the register at June 20, 2014. The full analyst notes on Severn Trent are available to download free of charge at:
Synergy Healthcare plc Analyst Notes
On June 24, 2014, Synergy Healthcare plc (Synergy Health) announced that the Company has filed an application with the UK Listing Authority for block listing of 700,000 new ordinary shares of 0.625 pence each to be included in the Official List and has also applied for the admission of shares for trading on the London Stock Exchange. The Company stated that the aforesaid shares shall rank equally ("pari passu") with the existing issued ordinary shares of the Company. The full analyst notes on Synergy Health are available to download free of charge at:
Dairy Crest Group plc Analyst Notes
On May 22, 2014, Dairy Crest Group plc (Dairy Crest) released its FY 2014 financial results (period ended March 31, 2014). The Company reported FY 2014 revenue of £1.4 billion, up 0.7% YoY. During the year, the Company's Dairies revenue declined 0.7% YoY to £944.8 million; Spreads revenue declined 8.8% YoY to £177.4 million, while Cheese revenue increased 14.4% YoY to £264.6 million. FY 2014 profit attributable to equity shareholders came in at £50.2 million or 36.4 pence per diluted share, compared to a profit of £46.6 million or 34.6 pence per diluted share in FY 2013. The Board has proposed a final dividend of 15.4 pence per share in addition to previously announced interim dividend of 5.9 pence. The final dividend will be paid on August 7, 2014 to shareholders of record on July 4, 2014. The AGM on July 15, 2014 will take a final call on dividend. The full analyst notes on Dairy Crest are available to download free of charge at:
Bodycote PLC Analyst Notes
Bodycote PLC (Bodycote) posted on the Financial Calendar section of its official website that the Company plans to release its H1 2014 financial results on July 31, 2014. Bodycote released its Q1 2014 results on April 29, 2014. Revenue for the period came in line with the Company's expectations at £153 million, up 2.8% YoY at constant exchange rates, but 2.2% YoY lower at actual exchange rates. Bodycote is a specialized plasma spray, high velocity oxy fuel and thermally formed ceramic treatments. The full analyst notes on Bodycote are available to download free of charge at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] earnings-review.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] earnings-review.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] earnings-review.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Earnings Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Earnings Review in this article or report according to the procedures outlined by Earnings Review. Earnings Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Earnings Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Earnings Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Earnings Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Earnings Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Earnings Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Earnings Review